Avelumab and Merkel Cell Carcinoma Prognosis: Is the Effect Permanent?

From General Health to Occupational Exposure Awareness

For decades, public health communication has centered on general wellness principles—balanced nutrition, routine screenings, and broad awareness of disease prevention. This foundational approach has served populations well, establishing a baseline understanding of how lifestyle factors and environmental exposures can influence long-term health outcomes. Within this legacy framework, discussions of cancer risk have typically focused on modifiable behaviors and population-level statistics, leaving more specialized contexts to clinical specialists. However, as therapeutic landscapes evolve, new intersections between medical treatment and occupational safety demand attention. The introduction of immunotherapies such as Avelumab has transformed cancer care, yet their use raises questions that extend beyond the clinic. Specifically, healthcare workers and pharmaceutical personnel who handle or administer these biologic agents may face unique exposure scenarios. This pivot from general health education to occupational exposure concern is not a departure from public health principles but rather an extension of them—applying the same vigilance about environmental risks to the workplace. Just as legacy messaging urged caution with known carcinogens, today’s occupational health frameworks must consider whether repeated contact with novel therapeutics carries implications for conditions like Merkel cell carcinoma. The transition from broad health guidance to targeted exposure awareness reflects a necessary maturation of risk communication in an era of increasingly specialized medical interventions.

Understanding Avelumab and Its Role in Merkel Cell Carcinoma

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It is approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with a poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/29799096/). The approval was based on the JAVELIN Merkel 200 trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Despite these advances, about 50% of patients with advanced MCC treated with immune checkpoint inhibitors (ICIs) progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). This raises the question of whether the effects of avelumab on MCC are permanent, which requires an examination of prognosis, mechanistic pathways, and risk considerations.

Prognosis and Durability of Response to Avelumab

Merkel cell carcinoma is associated with chronic ultraviolet light exposure and the Merkel cell polyoma virus, and it carries high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). The prognosis for patients with metastatic MCC is poor, with limited systemic therapy options historically. Avelumab was the first therapeutic agent specifically approved for this indication, and it is approved for use independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). However, the durability of response to avelumab is not guaranteed. In the JAVELIN Merkel 200 trial, avelumab showed promising ongoing responses, but the evidence indicates that a significant proportion of patients do not achieve a durable response (https://pubmed.ncbi.nlm.nih.gov/31543781/). For patients who are refractory to avelumab, efficient and safe treatment options are lacking, though combined ipilimumab plus nivolumab has shown activity in avelumab-refractory MCC in small studies (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/). In one multicenter study, three out of five avelumab-refractory patients responded to combined ipilimumab plus nivolumab according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). Another retrospective study noted that immune checkpoint inhibitors, including avelumab, offer durable responses and significant clinical benefit, but approximately 50% of patients progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). Thus, the permanence of avelumab's effect on MCC is not universal; while some patients achieve durable responses, many do not, and the disease can progress.

Mechanistic Pathways and Immune-Related Adverse Events

The mechanistic pathway linking avelumab to MCC involves immune checkpoint inhibition. Avelumab blocks PD-L1, which is expressed on tumor cells and immune cells, thereby preventing the inhibition of T-cell activity and enhancing the immune response against cancer cells (https://pubmed.ncbi.nlm.nih.gov/29799096/). However, this mechanism can also lead to immune-related adverse events (irAEs) due to overactivation of the immune system (https://pubmed.ncbi.nlm.nih.gov/31543781/). For example, a case report described hypercalcemia secondary to reactivation of sarcoidosis during avelumab treatment for metastatic MCC, which was managed with corticosteroids and allowed continuation of avelumab therapy (https://pubmed.ncbi.nlm.nih.gov/31543781/). This illustrates that while avelumab can be effective, it carries risks of irAEs that may complicate treatment and affect prognosis.

Risk Considerations and Adequacy of Warnings

Risk considerations include the adequacy of warnings regarding avelumab and MCC. The evidence indicates that avelumab is approved for metastatic MCC, and its use is associated with a risk of progression in about half of patients (https://pubmed.ncbi.nlm.nih.gov/35877101/). Warnings about the potential for lack of durable response and the need for alternative treatments in refractory cases are implicit in the literature, but the evidence does not provide specific details on labeling or patient counseling. Prognosis-related considerations for affected patients include the possibility of disease progression despite initial response, the need for subsequent therapies such as ipilimumab plus nivolumab, and the management of irAEs (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/31543781/). The timeline between exposure to avelumab and documented harm varies. In the case of irAEs like sarcoidosis reactivation, harm can occur during treatment, as seen with hypercalcemia (https://pubmed.ncbi.nlm.nih.gov/31543781/). For lack of efficacy, progression may be observed during or after treatment, with studies noting that about 50% of patients progress on ICI therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). The evidence does not specify a precise timeline, but the JAVELIN Merkel 200 trial assessed responses over time, and the retrospective studies included patients who were refractory to avelumab, indicating that harm from lack of efficacy can occur within the treatment period.

Summary: Is the Effect of Avelumab on Merkel Cell Carcinoma Permanent?

In summary, the permanence of avelumab's effect on Merkel cell carcinoma is not guaranteed. While it provides durable responses in some patients, approximately half of patients progress on therapy, and the disease can be refractory. The prognosis for affected patients depends on individual response, the potential for irAEs, and the availability of subsequent treatments. Warnings about these risks are supported by clinical trial data and real-world evidence, but the adequacy of such warnings in clinical practice is not directly addressed in the provided evidence. The timeline for harm includes both irAEs during treatment and progression during or after therapy.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Is the effect of Avelumab on Merkel cell carcinoma permanent?

No, the effect is not permanent for all patients. While some patients achieve durable responses, approximately 50% of patients with advanced Merkel cell carcinoma progress on immune checkpoint inhibitor therapy, including Avelumab (https://pubmed.ncbi.nlm.nih.gov/35877101/).

What is the prognosis for patients with metastatic Merkel cell carcinoma treated with Avelumab?

The prognosis varies. In the JAVELIN Merkel 200 trial, about one-third of patients with chemotherapy-refractory metastatic MCC responded to Avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). However, many patients do not achieve a durable response, and alternative treatments like ipilimumab plus nivolumab may be considered for refractory cases (https://pubmed.ncbi.nlm.nih.gov/33439294/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel cell carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.